Recombinant IL5 (Mepolizumab Biosimilar) antibody

Catalog No. ABIN7487818

This Mammalian Cells Monoclonal antibody specifically detects IL5 (Mepolizumab Biosimilar) in ELISA. It exhibits reactivity toward Human.

Quick Overview for Recombinant IL5 (Mepolizumab Biosimilar) antibody (ABIN7487818)

Target: IL5 (Mepolizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This IL5 (Mepolizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-IL5 (Mepolizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Mepolizumab Biosimilar - Anti-IL5 mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL5 (Mepolizumab Biosimilar)

Target: IL5 (Mepolizumab Biosimilar)

Target Type: Biosimilar

Background: SB-240563
Mepolizumab is a fully humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. (EGPA) and eosinophilia syndrome (HES). The pathogenesis of eosinophils is complex, but IL-5 is considered a key eosinophilic factor, involved in the differentiation, recruitment, activation and prolonged survival of eosinophils in peripheral tissues. Activated eosinophils further stimulate the inflammatory response, and also induce tissue damage and promote fibrosis, all of which contribute to the multifactorial symptoms of eosinophilic disease. Mepolizumab is used to treat severe asthma.

CAS-No: 196078-29-2